Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Ulcerative colitis currently has no medical cure, but surgery to remove the colon can eliminate the disease, and medications often produce long stretches of remission. Remission length varies widely, from a few months to many years, with studies suggesting about half of people relapse within a year while others stay symptom free for decades. Several factors shape that outcome, including medication adherence, the extent and severity of inflammation, infections, NSAID use, and stress, and important details are explained below.
Because flares can begin subtly with changes in stool frequency, urgency, blood, fatigue, or abdominal pain, tracking symptoms early can make a real difference in how quickly treatment is adjusted. Take a free, instant, online symptom check to better understand what your current symptoms may mean and what steps to consider next.
Last reviewed for medical accuracy: 10/01/2026
Ulcerative colitis (UC) is a chronic inflammatory condition of the colon and rectum. It causes symptoms such as abdominal pain, diarrhea, bleeding, fatigue and weight loss. Because UC is a lifelong condition, many patients ask: can ulcerative colitis be cured? While there is no definitive cure for UC at this time, advances in treatment allow most people to achieve and maintain remission—periods with few or no symptoms. Remission length varies from person to person, depending on disease severity, treatment choices and lifestyle factors.
Because the underlying cause remains unclear, no treatment “fixes” the immune system permanently. Instead, doctors focus on controlling inflammation, healing the gut lining and minimizing side effects.
Treatment choice depends on disease extent (proctitis vs. left-sided vs. pancolitis), severity (mild, moderate, severe) and your overall health.
Surgical removal of the colon (colectomy) essentially eliminates UC in the bowel. The most common procedure is proctocolectomy with ileal pouch–anal anastomosis (IPAA).
While colectomy can be considered a cure of colonic inflammation, it’s not without lifelong considerations. Discuss risks and benefits carefully with a colorectal surgeon if medications cannot control your UC.
Remission duration varies widely. Factors include:
Individual experiences vary. Some people stay symptom-free for years on the right regimen. Others need treatment adjustments more frequently.
Even in remission, watch for:
If you notice any of these, please speak to your doctor right away.
Not sure whether your symptoms are UC-related? You can try a free, online symptom check, using the doctor approved Ubie Symptom Checker to help guide your next steps.
If you experience any life-threatening or serious symptoms—such as severe bleeding, high fever or signs of dehydration—please speak to a doctor or go to the nearest emergency department immediately.
(References)
* Jackson EL, Hamlin PJ, Ford AC. VSL#3 and remission in active ulcerative colitis: larger studies required. Am J Gastroenterol. 2011 Mar;106(3):547; author reply 547-8. doi: 10.1038/ajg.2010.451. PMID: 21378771.
* He HH, Shen H, Gu PQ. [Prevention and treatment on remission of ulcerative colitis]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Feb;31(2):280-6. PMID: 21425592.
* Shimizu H, Arai K, Abe J, Nakabayashi K, Yoshioka T, Hosoi K, Kuroda M. Repeated fecal microbiota transplantation in a child with ulcerative colitis. Pediatr Int. 2016 Aug;58(8):781-5. doi: 10.1111/ped.12967. Epub 2016 Jun 21. PMID: 27324973.
* Velegraki M, Flamourakis M, Kazamias G, Georgiou G, Karmiris K. Replacement Resistant Iron Deficiency Anemia in a Patient With Ulcerative Colitis in Remission: Investigating Beyond the Obvious. Inflamm Bowel Dis. 2019 Sep 18;25(10):e123-e124. doi: 10.1093/ibd/izz152. PMID: 31301172.
* Kuwabara S, Tanimura S, Matsumoto S, Nakamura H, Horita T. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. Ann Rheum Dis. 2020 Aug;79(8):1125-1126. doi: 10.1136/annrheumdis-2019-216606. Epub 2020 Mar 25. PMID: 32213500.
* de Sire R, Castiglione F, Picardi M, Mascolo M, Di Luna I, Corcione F, D'Ambra M, Travaglino A, Rispo A. Chemotherapy-Induced Remission of Steroid-Dependent Ulcerative Colitis Associated With Rectal Hodgkin Lymphoma. Inflamm Bowel Dis. 2021 Jun 15;27(7):e81-e82. doi: 10.1093/ibd/izab010. PMID: 33501977.
* Lopes SR, Martins C, Teixeira M, Tomás D. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis. World J Gastroenterol. 2024 Sep 14;30(34):3929-3931. doi: 10.3748/wjg.v30.i34.3929. PMID: 39350781; PMCID: PMC11438653.
* Pedicelli A, Afif W. In active ulcerative colitis, risankizumab induced and maintained remission. Ann Intern Med. 2024 Nov;177(11):JC127. doi: 10.7326/ANNALS-24-02768-JC. Epub 2024 Nov 5. PMID: 39496179.
* Molander P, Af Björkesten CG, Henricson H, Koskela R, Nuutinen H, Käräjämäki A, Tillonen J, Tauriainen MM, Kellokumpu M, Eronen H, Suhonen UM, Vihriälä I, Hallinen T, Oksanen M, Soini E, Koivunen M, Kuronen M, Wirth D, Sipponen T. Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study. Eur J Gastroenterol Hepatol. 2025 Apr 1;37(4):446-453. doi: 10.1097/MEG.0000000000002939. Epub 2025 Feb 5. PMID: 39970041; PMCID: PMC11867796.
* Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD). Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. Adv Ther. 2026 Jul;43(7):3165-3186. doi: 10.1007/s12325-026-03622-3. Epub 2026 May 9. PMID: 42105145; PMCID: PMC13290896.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.